Verrica Pharmaceuticals Inc. (VRCA) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts VRCA Hot Sheet
Join SI Premium – FREE
Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.24), $0.03 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $180 thousand versus the consensus estimate of $257.6 thousand.
For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scotiabank Names Top Utility Stocks Amid Data Center Growth
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
